PROM1 and neoplasm: To improve the therapeutic efficacy of CAR T cells in an immunosuppressive tumor microenvironment, plasmids encoding CRISPR/Cas9 to disrupt the PD-1 gene and the piggyBac transposon to express CD133-specific CAR were cotransfected into human primary T cells.